FORM OF SERIES A WARRANT] RADIENT PHARMACEUTICALS CORPORATION Warrant To Purchase Common StockRADIENT PHARMACEUTICALS Corp • November 29th, 2011 • Pharmaceutical preparations • New York
Radient Pharmaceuticals Corporation, a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [_____________], the registered holder hereof or its permitted assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase from the Company, at the Exercise Price (as defined below) then in effect, at any time or times on or after the Issuance Date, but not after 11:59 p.m., New York time, on the Expiration Date, (as defined below), ______________ (_____________) fully paid, nonassessable shares of Common Stock (as defined below), subject to adjustment as provided herein (the “Warrant Shares”). Except as otherwise defined herein, capitalized terms in this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, this “Warrant”), shall have the meanings set forth in Section 17. This Warrant
AgreementAgreement • November 29th, 2011 • RADIENT PHARMACEUTICALS Corp • Pharmaceutical preparations • New York
THIS AGREEMENT (“Agreement”) is made and entered into this 28th day of November, 2011 between Whalehaven Capital Fund, Ltd. (“Whalehaven”) and Radient Pharmaceuticals Corporation (“RPC” or the “Company”). Whalehaven is hereinafter sometimes referred to as “Holder”, Whalehaven and RPC are hereinafter sometimes individually referred to as a “Party” and collectively as the “Parties.”
FORM OF SERIES B WARRANT] RADIENT PHARMACEUTICALS CORPORATION Warrant To Purchase Series C Convertible Preferred StockRADIENT PHARMACEUTICALS Corp • November 29th, 2011 • Pharmaceutical preparations • New York
Radient Pharmaceuticals Corporation, a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [_____________], the registered holder hereof or its permitted assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase from the Company, at the Exercise Price (as defined below) then in effect, at any time or times on or after the Issuance Date, but not after 11:59 p.m., New York time, on the Expiration Date, (as defined below), ______________ (_____________) fully paid, nonassessable shares of Series C Preferred Stock (as defined below), subject to adjustment as provided herein (the “Warrant Shares”). Except as otherwise defined herein, capitalized terms in this Warrant to Purchase Series C Convertible Preferred Stock (including any Warrants to Purchase Series C Convertible Preferred Stock issued in exchange, transfer or replacement hereof, this “Warrant”), s
EXCHANGE AGREEMENTExchange Agreement • November 29th, 2011 • RADIENT PHARMACEUTICALS Corp • Pharmaceutical preparations • New York
This EXCHANGE AGREEMENT (the “Agreement”), dated as of November 28, 2011 (the “Execution Date”), is made and entered into by and between Radient Pharmaceuticals Corporation, a Delaware corporation (the “Company”) and [_________________] (the “Holder”).
